Helen of Troy (HELE) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
3 Feb, 2026Executive summary
Net sales declined 12.2% year-over-year to $416.8 million for Q1 FY2025, driven by softer consumer demand, reduced retail orders, executional challenges, and global outdoor slowdown.
Adjusted diluted EPS fell to $0.99 from $1.94, and GAAP diluted EPS dropped to $0.26 from $0.94, impacted by higher tax expense and planned growth investments.
Operating margin decreased to 7.4% from 8.6%; adjusted operating margin dropped to 10.3% from 13.9%.
Project Pegasus restructuring continued, incurring $1.8 million in charges this quarter, with expected completion in fiscal 2025 and targeted $75–$85 million in annualized profit improvements by fiscal 2027.
Company is executing a "Reset & Revitalize" plan, increasing growth investment and focusing on brand health, innovation, and profit improvement actions.
Financial highlights
Net sales revenue: $416.8 million, down 12.2% year-over-year; gross profit margin improved to 48.7% from 45.4%–48.7%.
Adjusted EBITDA was $52.4 million (12.6% margin), down from $72.4 million (15.2% margin).
Cash flow from operations was $25.3 million, with free cash flow at $16.2 million, both down sharply year-over-year.
SG&A ratio increased to 40.9% from 35.3% due to higher marketing, distribution costs, and unfavorable operating leverage.
$100–$103 million spent on share repurchases in the quarter.
Outlook and guidance
FY2025 net sales outlook lowered to $1.885–$1.935 billion, implying a 6.0% to 3.5% decline.
Adjusted diluted EPS guidance reduced to $7.00–$7.50, a decline of 21.4%–15.8%.
Adjusted EBITDA now expected at $287–$297 million; free cash flow at $220–$240 million.
Net leverage ratio expected to end FY2025 at 1.6x–1.5x.
Assumes resolution of automation and ERP issues by end of Q2 and no improvement in consumer trends for the remainder of the year.
Latest events from Helen of Troy
- Sales up 8.2% to $402.1M; GAAP EPS $1.51; 2027 outlook raised amid margin and cost pressures.HELE
Q1 20279 Jul 2026 - Q2 sales and margins fell, but guidance, cash flow, and $500M buyback remain on track.HELE
Q2 20259 Jul 2026 - Net loss driven by asset impairments and lower sales, with guidance reflecting ongoing tariff headwinds.HELE
Q3 20268 Jul 2026 - Shareholders will vote on key governance, compensation, and equity plan changes amid ongoing transformation.HELE
Proxy filing24 Jun 2026 - Board recommends approval of all proposals, including director elections and compensation.HELE
Proxy filing24 Jun 2026 - Sales and margins fell on tariffs and impairments; FY27 targets recovery and debt reduction.HELE
Q4 202623 Apr 2026 - Prioritizing high-growth brands, revenue focus, and global expansion to drive long-term value.HELE
28th Annual ICR Conference 20263 Feb 2026 - All proposals passed as the company focuses on brand revitalization and operational transformation.HELE
AGM 202423 Jan 2026 - $240M acquisition of a high-growth nail brand, immediately accretive and diversifying the portfolio.HELE
M&A Announcement12 Jan 2026